| Antoinette Boameh, MD | |
|
941 Spring Creek Rd, Chattanooga, TN 37412-3909 | |
| (423) 855-3691 | |
| Not Available |
| Full Name | Antoinette Boameh |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 11 Years |
| Location | 941 Spring Creek Rd, Chattanooga, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194157610 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 54074 (Tennessee) | Secondary |
| 207R00000X | Internal Medicine | 54074 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tennova Health Care-cleveland | Cleveland, TN | Hospital |
| Fort Loudoun Medical Center | Lenoir city, TN | Hospital |
| Adventhealth Murray | Chatsworth, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hospital Medicine Services Of Tennessee Pc | 9234432881 | 140 |
| Southeastern Physician Services Pc | 0042307852 | 473 |
News Archive
Some advocates worry that a new focus on mental health issues could lead to unfair assumptions about patients and could keep them from seeking help.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.
New research into the cell-damaging effects of Huntington's disease suggests a potentially new approach for identifying possible therapeutic targets for treating the nerve-destroying disorder.
Digital health specialist Inhealthcare has launched a new app to remind patients to take their medicines on time.
› Verified 5 days ago
| Entity Name | Saint Thomas Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437194669 PECOS PAC ID: 1557269354 Enrollment ID: O20031230000470 |
News Archive
Some advocates worry that a new focus on mental health issues could lead to unfair assumptions about patients and could keep them from seeking help.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.
New research into the cell-damaging effects of Huntington's disease suggests a potentially new approach for identifying possible therapeutic targets for treating the nerve-destroying disorder.
Digital health specialist Inhealthcare has launched a new app to remind patients to take their medicines on time.
› Verified 5 days ago
| Entity Name | Memorial Health Partners Foundation, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922053545 PECOS PAC ID: 8022919570 Enrollment ID: O20040116000823 |
News Archive
Some advocates worry that a new focus on mental health issues could lead to unfair assumptions about patients and could keep them from seeking help.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.
New research into the cell-damaging effects of Huntington's disease suggests a potentially new approach for identifying possible therapeutic targets for treating the nerve-destroying disorder.
Digital health specialist Inhealthcare has launched a new app to remind patients to take their medicines on time.
› Verified 5 days ago
| Entity Name | Southeastern Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083835441 PECOS PAC ID: 0042307852 Enrollment ID: O20071025000571 |
News Archive
Some advocates worry that a new focus on mental health issues could lead to unfair assumptions about patients and could keep them from seeking help.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.
New research into the cell-damaging effects of Huntington's disease suggests a potentially new approach for identifying possible therapeutic targets for treating the nerve-destroying disorder.
Digital health specialist Inhealthcare has launched a new app to remind patients to take their medicines on time.
› Verified 5 days ago
| Entity Name | App Of Tennessee Hm, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396160768 PECOS PAC ID: 5395960694 Enrollment ID: O20140630001088 |
News Archive
Some advocates worry that a new focus on mental health issues could lead to unfair assumptions about patients and could keep them from seeking help.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.
New research into the cell-damaging effects of Huntington's disease suggests a potentially new approach for identifying possible therapeutic targets for treating the nerve-destroying disorder.
Digital health specialist Inhealthcare has launched a new app to remind patients to take their medicines on time.
› Verified 5 days ago
| Entity Name | Hospital Medicine Services Of Tennessee Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528433802 PECOS PAC ID: 9234432881 Enrollment ID: O20160114002673 |
News Archive
Some advocates worry that a new focus on mental health issues could lead to unfair assumptions about patients and could keep them from seeking help.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.
New research into the cell-damaging effects of Huntington's disease suggests a potentially new approach for identifying possible therapeutic targets for treating the nerve-destroying disorder.
Digital health specialist Inhealthcare has launched a new app to remind patients to take their medicines on time.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Antoinette Boameh, MD 941 Spring Creek Road, Chattanooga, TN 37421-7519 Ph: (423) 855-3691 | Antoinette Boameh, MD 941 Spring Creek Rd, Chattanooga, TN 37412-3909 Ph: (423) 855-3691 |
News Archive
Some advocates worry that a new focus on mental health issues could lead to unfair assumptions about patients and could keep them from seeking help.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.
New research into the cell-damaging effects of Huntington's disease suggests a potentially new approach for identifying possible therapeutic targets for treating the nerve-destroying disorder.
Digital health specialist Inhealthcare has launched a new app to remind patients to take their medicines on time.
› Verified 5 days ago
Dr. Pamela Rani Sud, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 725 Glenwood Drive, Suite E-500, Chattanooga, TN 37404 Phone: 423-495-2635 Fax: 423-495-2638 | |
David Shved, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 975 E 3rd St, Chattanooga, TN 37403 Phone: 423-778-5179 Fax: 423-778-2108 | |
Megan J Coylewright, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 975 E 3rd St, Chattanooga, TN 37403 Phone: 423-778-8258 | |
Dr. Charles Robert Bosshardt, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2515 Desales Ave Ste 206, Chattanooga, TN 37404 Phone: 423-698-8101 Fax: 423-698-3450 | |
Dr. Elise Helene Marshall, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 605 Glenwood Dr Ste 300, Chattanooga, TN 37404 Phone: 423-495-2690 Fax: 423-495-2698 | |
Dr. Joshua Warner Hornsby, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 979 E 3rd St Ste A-440, Chattanooga, TN 37403 Phone: 423-778-2867 Fax: 423-778-2866 | |
Dr. Donald Franklin Mackler, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 721 Glenwood Dr, Ste. W552, Chattanooga, TN 37404 Phone: 423-629-6258 Fax: 423-629-9531 |